Study design and rationale of a dose-ranging trial of LX4211, a dual inhibitor of SGLT1 and SGLT2, in type 2 diabetes inadequately controlled on metformin monotherapy

Clinical Cardiology

Volumn 36, Issue 7, 2013, Pages 367-371

  Lapuerta, Pablo ^a   Rosenstock, Julio ^b   Zambrowicz, Brian ^a   Powell, David R ^a   Ogbaa, Ike ^a   Freiman, Joel ^a   Cefalu, William T ^c   Banks, Phillip ^a   Frazier, Kenny ^a   Kelly, Mike ^a   Sands, Arthur ^a  

^a LEXICON PHARMACEUTICALS INC   (United States)

^b DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^c PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; LX 4211; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); URINARY TRACT INFECTION;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; CLINICAL PROTOCOLS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL DISEASES; GLYCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; RESEARCH DESIGN; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2; TIME FACTORS; TREATMENT FAILURE; UNITED STATES; URINARY TRACT INFECTIONS;

EID: 84879846197     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22125     Document Type: Article

References (18)

1. Poitout V, Robertson RP,. Glucolipotoxicity: fuel excess and β-cell dysfunction. Endocr Rev. 2008; 29: 351-366.
2. Bolinder J, Ljunggren Ö, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012; 97: 1020-1031.
3. Musso G, Gambino R, Cassader M, et al. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials. Ann Med. 2012; 44: 375-393.
4. Plosker GL,. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012; 72: 2289-2312.
5. Wright EM, Loo DD, Hirayama BA,. Biology of human sodium glucose transporters. Physiol Rev. 2011; 91: 733-794.
6. Albertoni Borghese MF, Majowicz MP,. Inhibitors of sodium/glucose cotransport. Drugs Future. 2009; 34: 297-305.
7. Goldring W, Welsh C,. The effects on renal activity of the oral administration of phlorizin in man. J Clin Invest. 1934; 13: 749-752.
8. Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012; 92: 158-169.
9. Desjeux JF, Turk E, Wright E,. Congenital selective Na D-glucose cotransport defects leading to renal glycosuria and congenital selective intestinal malabsorption of glucose and galactose. In:, Scriver CR, Beaudet AL, Sly WS, et al, eds. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York, NY: McGraw Hill; 1995: 3563-3580.
10. Xin B, Wang H,. Multiple sequence variations in SLC5A1 gene are associated with glucose-galactose malabsorption in a large cohort of Old Order Amish. Clin Genet. 2011; 79: 86-91.
11. Powell DR, Smith M, Zhao S, et al. LX4211 increases serum GLP-1 and PYY levels after oral glucose challenge in mice by inhibiting SGLT1-mediated intestinal glucose absorption. Abstract presented at: 72nd Annual Meeting of the American Diabetes Association; June 8-12, 2012; Philadelphia, PA.
12. Powell DR, Dacosta C, Gay J, et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrin Metab. 2013 Jan 15; 304 (2): E117-30.
13. Freiman J, Ye G, Ogbaa I, et al. LX4211, a dual SGLT1/SGLT2 inhibitor, shows a favorable gastrointestinal and genitourinary safety profile in type 2 diabetes mellitus (T2DM) patients and healthy subjects. Abstract presented at: 72nd Annual Meeting of the American Diabetes Association; June 8-12, 2012; Philadelphia, PA. Presentation 773.
14. Baggio LL, Drucker DJ,. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007; 132: 2131-2157.
15. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature. 2002; 418: 650-654.
16. Chen J, Williams S, Ho S, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 2010; 1: 57-92.
17. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, MA: Little, Brown & Co; 1994: 253-256.
18. AMARYL [Package insert]. http://www.accessdata.fda.gov/drugsatfda-does/ label/2012/020496s022lbl.pdf. Accessed April 9, 2013.